Do analysts recommend CLRB or JUNS?

Cellectar Biosciences presently has a consensus price target of $11.00, indicating a potential upside of 334.78%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Cellectar Biosciences is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CLRB or JUNS more profitable?

Cellectar Biosciences' return on equity of -185.35% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -185.35% -115.42% Jupiter Neurosciences N/A -1,314.62% -246.66%

Does the media prefer CLRB or JUNS?

In the previous week, Jupiter Neurosciences had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 3 mentions for Jupiter Neurosciences and 2 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.93 beat Jupiter Neurosciences' score of 0.83 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jupiter Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer JUNS or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ABVC or JUNS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABVC or JUNS more profitable?

ABVC BioPharma's return on equity of -47.68% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -47.68% -30.97% Jupiter Neurosciences N/A -1,314.62% -246.66%

Do analysts recommend JUNS or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend JUNS or PLRZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, JUNS or PLRZ?

Polyrizon has lower revenue, but higher earnings than Jupiter Neurosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jupiter Neurosciences $64.69K 58.99 -$8.65M -$19.12 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is JUNS or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Jupiter Neurosciences N/A -1,314.62% -246.66% Polyrizon N/A N/A N/A

Jupiter Neurosciences (JUNS) Competitors

$4.18 -0.71 (-14.52%)

As of 08/28/2026 04:00 PM Eastern

Compare

JUNS vs. CLRB, TXMD, ABVC, BFRI, and PLRZ

Should you buy Jupiter Neurosciences stock or one of its competitors? Jupiter Neurosciences's main competitors and comparable companies include Cellectar Biosciences (CLRB), TherapeuticsMD (TXMD), ABVC BioPharma (ABVC), Biofrontera (BFRI), and Polyrizon (PLRZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Jupiter Neurosciences compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, Jupiter Neurosciences had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 3 mentions for Jupiter Neurosciences and 2 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.93 beat Jupiter Neurosciences' score of 0.83 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jupiter Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectar Biosciences' return on equity of -185.35% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-185.35%	-115.42%
Jupiter Neurosciences	N/A	-1,314.62%	-246.66%

Jupiter Neurosciences has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A
Jupiter Neurosciences	$64.69K	58.99	-$8.65M	-$19.12	N/A

Cellectar Biosciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market.

Cellectar Biosciences presently has a consensus price target of $11.00, indicating a potential upside of 334.78%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Cellectar Biosciences is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

16.4% of Cellectar Biosciences shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Cellectar Biosciences beats Jupiter Neurosciences on 9 of the 15 factors compared between the two stocks.

How does Jupiter Neurosciences compare to TherapeuticsMD?

Jupiter Neurosciences (NASDAQ:JUNS) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

TherapeuticsMD has higher revenue and earnings than Jupiter Neurosciences. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$64.69K	58.99	-$8.65M	-$19.12	N/A
TherapeuticsMD	$3.02M	8.51	-$570K	$0.02	111.00

In the previous week, Jupiter Neurosciences had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for Jupiter Neurosciences and 1 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 1.89 beat Jupiter Neurosciences' score of 0.83 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Jupiter Neurosciences	Positive
TherapeuticsMD	Very Positive

Jupiter Neurosciences has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-246.66%
TherapeuticsMD	-6.64%	-1.09%	-0.78%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

30.7% of TherapeuticsMD shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Jupiter Neurosciences has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Summary

TherapeuticsMD beats Jupiter Neurosciences on 8 of the 13 factors compared between the two stocks.

How does Jupiter Neurosciences compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

11.4% of ABVC BioPharma shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ABVC BioPharma has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Jupiter Neurosciences had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Jupiter Neurosciences and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.89 beat Jupiter Neurosciences' score of 0.83 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
ABVC BioPharma	Very Positive
Jupiter Neurosciences	Positive

ABVC BioPharma's return on equity of -47.68% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Jupiter Neurosciences	N/A	-1,314.62%	-246.66%

ABVC BioPharma has higher revenue and earnings than Jupiter Neurosciences. ABVC BioPharma is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	43.37	-$7.91M	-$0.30	N/A
Jupiter Neurosciences	$64.69K	58.99	-$8.65M	-$19.12	N/A

Summary

ABVC BioPharma beats Jupiter Neurosciences on 7 of the 12 factors compared between the two stocks.

How does Jupiter Neurosciences compare to Biofrontera?

Jupiter Neurosciences (NASDAQ:JUNS) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Jupiter Neurosciences has higher earnings, but lower revenue than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$64.69K	58.99	-$8.65M	-$19.12	N/A
Biofrontera	$41.71M	0.57	-$10.54M	-$0.45	N/A

In the previous week, Jupiter Neurosciences had 1 more articles in the media than Biofrontera. MarketBeat recorded 3 mentions for Jupiter Neurosciences and 2 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.44 beat Jupiter Neurosciences' score of 0.83 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Overall Sentiment
Jupiter Neurosciences	Positive
Biofrontera	Positive

10.1% of Biofrontera shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by insiders. Comparatively, 8.1% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Jupiter Neurosciences has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-246.66%
Biofrontera	-13.78%	-145.81%	-31.30%

Jupiter Neurosciences has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market. Comparatively, Biofrontera has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Summary

Biofrontera beats Jupiter Neurosciences on 8 of the 15 factors compared between the two stocks.

How does Jupiter Neurosciences compare to Polyrizon?

Jupiter Neurosciences (NASDAQ:JUNS) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Polyrizon's return on equity of 0.00% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-246.66%
Polyrizon	N/A	N/A	N/A

Jupiter Neurosciences has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.5, suggesting that its share price is 250% less volatile than the broader market.

Polyrizon has lower revenue, but higher earnings than Jupiter Neurosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$64.69K	58.99	-$8.65M	-$19.12	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Jupiter Neurosciences had 1 more articles in the media than Polyrizon. MarketBeat recorded 3 mentions for Jupiter Neurosciences and 2 mentions for Polyrizon. Jupiter Neurosciences' average media sentiment score of 0.83 beat Polyrizon's score of 0.43 indicating that Jupiter Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Jupiter Neurosciences	Positive
Polyrizon	Neutral

Summary

Jupiter Neurosciences beats Polyrizon on 4 of the 7 factors compared between the two stocks.

Get Jupiter Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JUNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JUNS vs. The Competition

Export

Metric	Jupiter Neurosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.82M	$12.17B	$7.21B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-0.22	787.65	273.16	25.42
Price / Sales	58.99	755.84	630.81	94.42
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	-1.05	10.49	11.08	6.36
Net Income	-$8.65M	$2.83B	$3.48B	$349.79M
7 Day Performance	-32.58%	0.39%	0.13%	-0.80%
1 Month Performance	-42.84%	5.34%	7.08%	4.13%
1 Year Performance	-96.21%	6.05%	24.67%	15.17%

Jupiter Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JUNS Jupiter Neurosciences	0.7987 of 5 stars	$4.18 -14.5%	N/A	-96.2%	$3.82M	$64.69K	N/A	5	News Coverage Upcoming Earnings Short Interest Decrease Gap Up
CLRB Cellectar Biosciences	2.7121 of 5 stars	$2.60 +0.4%	$11.00 +323.1%	-48.0%	$24.57M	N/A	N/A	10
TXMD TherapeuticsMD	1.5936 of 5 stars	$2.06 +1.5%	N/A	+100.0%	$23.83M	$3.02M	103.00	420	Analyst Downgrade
ABVC ABVC BioPharma	0.826 of 5 stars	$0.88 -1.1%	N/A	-70.7%	$23.46M	N/A	N/A	30	Positive News Gap Up
BFRI Biofrontera	1.4714 of 5 stars	$1.50 +1.3%	N/A	+79.4%	$22.26M	$41.71M	N/A	70	Positive News Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JUNS) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jupiter Neurosciences (JUNS) Competitors

JUNS vs. CLRB, TXMD, ABVC, BFRI, and PLRZ

How does Jupiter Neurosciences compare to Cellectar Biosciences?

Summary

How does Jupiter Neurosciences compare to TherapeuticsMD?

Summary

How does Jupiter Neurosciences compare to ABVC BioPharma?

Summary

How does Jupiter Neurosciences compare to Biofrontera?

Summary

How does Jupiter Neurosciences compare to Polyrizon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS vs. The Competition

Jupiter Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jupiter Neurosciences (JUNS) Competitors

JUNS vs. CLRB, TXMD, ABVC, BFRI, and PLRZ

How does Jupiter Neurosciences compare to Cellectar Biosciences?

Does the media prefer CLRB or JUNS?

Is CLRB or JUNS more profitable?

Which has stronger earnings & valuation, CLRB or JUNS?

Which has more risk & volatility, CLRB or JUNS?

Do analysts recommend CLRB or JUNS?

Do institutionals & insiders have more ownership in CLRB or JUNS?

Summary

How does Jupiter Neurosciences compare to TherapeuticsMD?

Which has better earnings & valuation, JUNS or TXMD?

Does the media refer more to JUNS or TXMD?

Is JUNS or TXMD more profitable?

Do analysts prefer JUNS or TXMD?

Do institutionals & insiders hold more shares of JUNS or TXMD?

Which has more risk & volatility, JUNS or TXMD?

Summary

How does Jupiter Neurosciences compare to ABVC BioPharma?

Do institutionals and insiders hold more shares of ABVC or JUNS?

Which has more risk & volatility, ABVC or JUNS?

Do analysts recommend ABVC or JUNS?

Does the media favor ABVC or JUNS?

Is ABVC or JUNS more profitable?

Which has higher valuation and earnings, ABVC or JUNS?

Summary

How does Jupiter Neurosciences compare to Biofrontera?

Do analysts recommend JUNS or BFRI?

Which has stronger valuation and earnings, JUNS or BFRI?

Does the media favor JUNS or BFRI?

Do institutionals & insiders have more ownership in JUNS or BFRI?

Is JUNS or BFRI more profitable?

Which has more risk and volatility, JUNS or BFRI?

Summary

How does Jupiter Neurosciences compare to Polyrizon?

Is JUNS or PLRZ more profitable?

Which has more risk and volatility, JUNS or PLRZ?

Which has higher earnings and valuation, JUNS or PLRZ?

Do analysts recommend JUNS or PLRZ?

Does the media prefer JUNS or PLRZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS vs. The Competition

Jupiter Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools